Personalis, Inc. PSNL
Nasdaq · XNAS · stock · Services-Medical Laboratories
Chart by TradingView
3/9
Piotroski F — financial health
0.31
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $69.6M | -$81.3M | — | -$79.5M | $261.2M |
| 2024 | $84.6M | -$81.3M | — | -$46.8M | $203.0M |
| 2023 | $73.5M | -$108.3M | — | -$67.2M | $129.4M |
| 2022 | $65.0M | -$113.3M | — | -$120.1M | $218.1M |
| 2021 | $85.5M | -$65.2M | — | -$81.9M | $310.3M |
| 2020 | $78.6M | -$41.3M | — | -$45.9M | $194.9M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.31 (distress)
- Working capital / assets 0.683
- Retained earnings / assets -1.889
- EBIT / assets -0.264
- Equity / liabilities 3.579
Source: SEC EDGAR filings · CIK 0001527753 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.